Abstract: Objective: To assess the efficacy and safety of baricitinib in the treatment of patient with progressive vitiligo. Methods: Patients with vitiligo received baritinib from April 2021 to March 2022 due to failure of systemic hormone therapy or refusal to use glucocorticoids were collected and evaluated at 3 and 6 months. Results: 8 patients were collected. After 3 and 6 months of treatment, the significant efficiency was 35.3% and 55.9%, and the total effective rate was 67.6% and 73.5%, respectively. After 6 months of treatment, the efficacy of extremities was lower than that of trunk (total effective rate χ²=7.369, P<0.01) and limbs (total effective rate χ²=4.554, P<0.05).  Conclusion: Baricitinib is effective and safe for progressive vitiligo，which is affected by duration of treatment and location of lesions.

Key words: vitiligo, JAK inhibitors, baricitinib